BeiGene announced in an SEC filing that it and Novartis have entered into a mutual termination and release agreement, terminating their agreement (announced on 19 December 2021) under which BeiGene granted Novartis an exclusive time-based option to receive an exclusive licence to develop, manufacture and commercialise ociperlimab. BeiGene will continue enrolment in the phase III AdvanTIG 302 trial of ociperlimab in combination with BeiGene’s PD-1 inhibitor tislelizumab for the first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations.
Earlier this year on 18 January, China’s National Reimbursement Drug List was updated to include four new indications tislelizumab.